Welcome to LookChem.com Sign In|Join Free

CAS

  • or

333986-94-0

Post Buying Request

333986-94-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

333986-94-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 333986-94-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,3,9,8 and 6 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 333986-94:
(8*3)+(7*3)+(6*3)+(5*9)+(4*8)+(3*6)+(2*9)+(1*4)=180
180 % 10 = 0
So 333986-94-0 is a valid CAS Registry Number.

333986-94-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 4-[(4-nitrophenyl)sulfanyl]piperidine-1-carboxylate

1.2 Other means of identification

Product number -
Other names tert-Butyl 4-[(4-Nitrophenyl)sulfanyl)-1-piperidinecarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:333986-94-0 SDS

333986-94-0Relevant articles and documents

NOVEL IMIDAZO-PYRAZINE DERIVATIVES

-

Page/Page column 45; 145, (2021/12/31)

The invention provides novel imidazo-pyrazine derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, m, n, and R1to R3 are as described herein: formula (I). Further provided are pharmace

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

-

Paragraph 0087, (2016/09/26)

no abstract published

TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

-

, (2011/06/16)

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 333986-94-0